CombiMatrix Corporation to Release 2017 First Quarter Financial Results on May 4, 2017
April 27 2017 - 6:00AM
CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular
diagnostics company specializing in DNA-based reproductive health
and pediatric testing services, announces that it will release
financial results for the three months ended March 31, 2017 after
market close on Thursday, May 4, 2017. CombiMatrix management
will hold an investment community conference call at 4:30 p.m.
Eastern time (1:30 p.m. Pacific time) to discuss those results and
answer questions.
Live Call: |
U.S.: |
(866) 634-2258 |
|
International: |
(330) 863-3454 |
|
|
|
Live Webcast: |
|
http://investor.combimatrix.com/events.cfmThe webcast replay will
be archived for 30 days |
|
|
|
Replay: |
U.S.: |
(855) 859-2056 |
|
International: |
(404) 537-3406 |
|
Passcode: |
10856966 |
|
|
The telephone replay
will be available for seven days |
About CombiMatrix
Corporation
CombiMatrix Corporation provides best-in-class
molecular diagnostic solutions and comprehensive clinical support
to foster the highest quality in patient care. CombiMatrix
specializes in pre-implantation genetic diagnostics and screening,
prenatal diagnosis, miscarriage analysis and pediatric
developmental disorders, offering DNA-based testing for the
detection of genetic abnormalities beyond what can be identified
through traditional methodologies. Our testing focuses on advanced
technologies, including single nucleotide polymorphism chromosomal
microarray analysis, next-generation sequencing, fluorescent in
situ hybridization and high resolution karyotyping.
Additional information about CombiMatrix is available at
www.combimatrix.com or by calling (800) 710-0624.
Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
(949) 753-0624
Investor Contact:
LHA
Jody Cain
(310) 691-7100
jcain@lhai.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Sep 2023 to Sep 2024